Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
Advances in acute myeloid leukemia: recently approved therapies and drugs in development
Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …
Acute myeloid leukemia: current progress and future directions
H Kantarjian, T Kadia, C DiNardo, N Daver… - Blood cancer …, 2021 - nature.com
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
Next generation sequencing in AML—on the way to becoming a new standard for treatment initiation and/or modulation?
M Leisch, B Jansko, N Zaborsky, R Greil, L Pleyer - Cancers, 2019 - mdpi.com
Acute myeloid leukemia (AML) is a clonal disease caused by genetic abberations occurring
predominantly in the elderly. Next generation sequencing (NGS) analysis has led to a …
predominantly in the elderly. Next generation sequencing (NGS) analysis has led to a …
Treatment of relapsed/refractory acute myeloid leukemia
P Bose, P Vachhani, JE Cortes - Current treatment options in oncology, 2017 - Springer
Opinion statement Approximately 40–45% of younger and 10–20% of older adults with
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …
Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance
M Levin, M Stark, Y Ofran, YG Assaraf - Cancer cell international, 2021 - Springer
Background Acute myeloid leukemia (AML) remains a devastating disease with a 5-year
survival rate of less than 30%. AML treatment has undergone significant changes in recent …
survival rate of less than 30%. AML treatment has undergone significant changes in recent …
Current and future molecular targets for acute myeloid leukemia therapy
SA Sami, NHE Darwish, ANM Barile… - Current treatment options …, 2020 - Springer
Opinion statement Acute myeloid leukemia (AML) disease prognosis is poor and there is a
high risk of chemo-resistant relapse for both young and old patients. Thus, there is a …
high risk of chemo-resistant relapse for both young and old patients. Thus, there is a …
Acute myeloid leukemia: from mutation profiling to treatment decisions
C DiNardo, C Lachowiez - Current hematologic malignancy reports, 2019 - Springer
Abstract Purpose of Review Awareness of the molecular landscape of AML has improved
AML care over the last 5 years. This review summarizes updates regarding the diagnostic …
AML care over the last 5 years. This review summarizes updates regarding the diagnostic …
Management of acute myeloid leukemia: current treatment options and future perspectives
M Fleischmann, U Schnetzke, A Hochhaus, S Scholl - Cancers, 2021 - mdpi.com
Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …
[HTML][HTML] Differentiation therapy of myeloid leukemia: four decades of development
V Madan, HP Koeffler - Haematologica, 2021 - ncbi.nlm.nih.gov
Acute myeloid leukemia is characterized by arrested differentiation, and agents that
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …
overcome this block are therapeutically useful, as shown by the efficacy of all-trans retinoic …